GE HealthCare’s Pristina Recon DL tool has received pre-market authorisation (PMA) from the US Food and Drug Administration (FDA).

Recon DL is a 3D mammography image reconstruction technology available as an upgradeable feature on GE HealthCare’s Pristina Via platform. It uses two deep learning (DL) models in tandem to separate meaningful signals from noise in mammography images.

GE HealthCare claims that Recon DL is the first mammography technology to use deep learning in combination with iterative reconstruction to improve digital breast tomosynthesis (DBT) image quality.